2016 saw slump in FDA drug approvals, but 2017 could be return to form
FDA approvals could rebound in 2017 – but concerns about big pharma R&D productivity won’t go away.
X
2016 saw slump in FDA drug approvals, but 2017 could be return to form
https://pharmaphorum.com/views-and-analysis/2016-saw-slump-fda-drug-approvals-2017-return-form/
